Pharvaris CMO sells 7,101 shares after option exercise

Rhea-AI Filing Summary

Pharvaris N.V. Chief Medical Officer Lu Peng executed a small, pre-planned option exercise-and-sell transaction under a Rule 10b5-1 trading plan. On April 22–23, 2026, Peng exercised options to acquire 7,101 shares of common stock at $2.59 per share and sold the same 7,101 shares in open-market transactions around $30 per share.

After these trades, Peng directly holds 66,083 shares of common stock and 106,207 stock options expiring in 2030. The filing characterizes the activity as a scheduled transaction pursuant to a Rule 10b5-1 trading plan, indicating it was arranged in advance rather than timed opportunistically.

Insights

Equity compensation and insider-trading analyst

Routine 10b5-1 option exercise-and-sell, modest versus CMO’s remaining stake.

The Chief Medical Officer of Pharvaris N.V., Lu Peng, exercised stock options to acquire 7,101 common shares at $2.59 and sold the same number of shares around $30. This is a classic exercise-and-sell to monetize vested equity.

Footnotes describe the activity as a scheduled transaction under a Rule 10b5-1 trading plan, meaning the trades were pre-arranged, which typically reduces the informational value of their timing. After the transactions, Peng still holds 66,083 shares plus 106,207 options expiring in 2030, so the sale represents only a portion of the overall exposure.

Insider Trade Summary 10b5-1

Exercise and Sale: 7,101 shares ($195K approx. pre-tax spread)

Exercise and Sale 6 txns

Insider Lu Peng

Role Chief Medical Officer

Sold 7,101 shs ($213K)

Approx. gross sale proceeds $213K

Approx. exercise cost $18K

Approx. pre-tax spread $195K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	100	$0.00	$0.00
Exercise	Common Stock	100	$2.59	$259.00
Sale	Common Stock	100	$30.03	$3K
Exercise	Stock Option (Right to Buy)	7,001	$0.00	$0.00
Exercise	Common Stock	7,001	$2.59	$18K
Sale	Common Stock	7,001	$30.0531	$210K

Holdings After Transaction: Stock Option (Right to Buy) — 106,207 contracts (Direct); Common Stock — 66,083 shares (Direct)

Footnotes (4)

1. F1. This is a scheduled exercise and sale from 10b5-1 trading plan.
2. F2. These shares were sold in multiple transactions at prices ranging from $30 - $30.15.
3. F3. These shares were sold in multiple transactions at prices ranging from $30.03 - $31.0299.
4. F4. 25% of the option vested on February 3, 2020 with the remaining shares vesting in 1/48 monthly installments thereafter.

Key Figures

Shares sold: 7,101 shares Sale price per share: $30.0531 and $30.03 Options exercise price: $2.59 per share +3 more

6 metrics

Shares sold 7,101 shares Common stock sold in open-market transactions on April 22–23, 2026

Sale price per share $30.0531 and $30.03 Average prices for April 22 and April 23, 2026 sales

Options exercise price $2.59 per share Conversion or exercise price for 7,101 stock options

Shares held after 66,083 shares Total Pharvaris common stock directly owned after transactions

Remaining stock options 106,207 options Stock Option (Right to Buy) position after reported exercises

Option expiration February 3, 2030 Expiration date for the exercised stock option grant

Key Terms

Rule 10b5-1 trading plan, Stock Option (Right to Buy), open-market sale, derivative exercise/conversion, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"This is a scheduled exercise and sale from 10b5-1 trading plan."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Stock Option (Right to Buy) financial

"security_title": "Stock Option (Right to Buy)""

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

derivative exercise/conversion financial

"transaction_action": "derivative exercise/conversion""

multiple transactions financial

"These shares were sold in multiple transactions at prices ranging"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Pharvaris (PHVS) CMO Lu Peng report in this Form 4?

Lu Peng reported exercising stock options for 7,101 Pharvaris common shares at $2.59 and selling 7,101 shares in open-market trades around $30. The filing describes these as scheduled transactions under a Rule 10b5-1 trading plan, indicating they were pre-arranged.

How many Pharvaris (PHVS) shares did the CMO sell and at what prices?

Lu Peng sold 7,101 Pharvaris common shares in multiple open-market transactions at prices around $30 per share. Footnotes note ranges of $30–$30.15 and $30.03–$31.0299, with the reported average prices of $30.0531 and $30.03 per share.

What stock options did Pharvaris (PHVS) CMO Lu Peng exercise?

Lu Peng exercised stock options labeled as “Stock Option (Right to Buy)” covering 7,101 shares of Pharvaris common stock at a conversion or exercise price of $2.59 per share. These options were part of a grant that vested over time and expire on February 3, 2030.

How many Pharvaris (PHVS) shares does the CMO hold after these transactions?

Following the reported transactions, Lu Peng directly holds 66,083 shares of Pharvaris common stock. In addition, the derivative table shows 106,207 remaining stock options after the exercises, providing further potential equity exposure if those options are exercised in the future.

Were Pharvaris (PHVS) CMO Lu Peng’s trades under a Rule 10b5-1 plan?

Yes. A footnote explicitly states the exercise and sale were scheduled under a Rule 10b5-1 trading plan. Such plans pre-arrange trades in advance, helping separate routine liquidity events from discretionary market-timing decisions by insiders like the Chief Medical Officer.

What is the significance of the Rule 10b5-1 plan in this Pharvaris Form 4?

The Rule 10b5-1 reference indicates Lu Peng’s options exercises and share sales were pre-planned rather than reactive to short-term news. For investors, this usually frames the transactions as routine compensation-related activity instead of signaling a change in the insider’s confidence.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/24/2026 - 11:27 AM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lu Peng

(Last) (First) (Middle)

1 CRANBERRY HILL SUITE 400

(Street)

LEXINGTON MASSACHUSETTS 02421

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pharvaris N.V. [ PHVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/22/2026		M(1)		7,001	A	$2.59	73,084	D
Common Stock	04/22/2026		S(1)		7,001	D	$30.0531(2)	66,083	D
Common Stock	04/23/2026		M(1)		100	A	$2.59	66,183	D
Common Stock	04/23/2026		S(1)		100	D	$30.03(3)	66,083	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.59	04/22/2026		M(1)			7,001	(4)	02/03/2030	Common Stock	7,001	$0	106,307	D
Stock Option (Right to Buy)	$2.59	04/23/2026		M(1)			100	(4)	02/03/2030	Common Stock	100	$0	106,207	D

Explanation of Responses:

1. This is a scheduled exercise and sale from 10b5-1 trading plan.

2. These shares were sold in multiple transactions at prices ranging from $30 - $30.15.

3. These shares were sold in multiple transactions at prices ranging from $30.03 - $31.0299.

4. 25% of the option vested on February 3, 2020 with the remaining shares vesting in 1/48 monthly installments thereafter.

	/s/ Marnus Nel, Attorney-in-Fact for Peng Lu	04/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)